Fig. 5

a miR-28-5p and miR-650 inhibitors treated groups show significantly greater percentage of average apoptosis in all CLL primary cells compared to NC (32.10% vs. 21.53%, P = 0.006; 34.79% vs. 21.53%, P < 0.001). b miR-28-5p and miR-650 inhibitors treated groups also show greater percentage of average apoptosis compared to NC in CLL primary cells without p53 aberrations (37.75% vs. 23.97%, P = 0.005; 41.68% vs. 23.97%, P < 0.001). c No increase apoptosis in CLL primary cells with p53 aberrations was observed in miR-28-5p and miR-650 inhibitors treated groups compared to NC (17.05% vs.15.16%, P = 0.305, 16.43% vs. 15.15%, P = 0.519). d Higher apoptosis percentage (R1 + R2) was seen in primary CLL cells without p53 aberrations treated with miR-28-5p- (41.32% vs. 19.05%) and miR-650- (41.09% vs. 19.05%) inhibitors groups than the apoptosis percentage of cells treated with miR-NC. e No increased apoptosis rates were found in primary CLL harboring p53 aberrations with miR-28-5p- (16.36% vs. 16.58%) and miR-650- (16.26% vs. 16.58%) inhibitors groups compared to the apoptosis rates treated with miR-NC. Y-axis: number of cells stained with PI; X-axis: cells stained with Annexin V–FITC. Apoptotic cells are in R1 and R2